Essential Fatty Acid Nutrition For 1-2 Yr-Olds
Essential Fatty Acid Nutrition in Infants 1 to 2 Years-of-Age
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z4H4
- BC Children's Hospital Research Institute, University of British Columbia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- term gestation (37-41 weeks gestation and 2500g or more at birth)
- single birth
- English as the primary language in the home
- non-smoking home environment
- a healthy infant not yet 13 months-of-age, who is not currently breast-fed or fed infant formula with ARA and DHA.
- primary milk source is cows' milk, cows' milk substitutes, or other milk substitutes containing no supplemental fatty acids from enrollment to 24 months-of age.
- the infant has no known food allergies, metabolic, neurological, genetic, or immune disorders that are likely, in the opinion of the investigator to impact the outcome measures in this study.
- the infant has not been fatty acid or oil, including fish oil supplements and there is no intent to provide these supplements during the study.
- the infant has no history of hospitalization, growth failure or any other event which in the opinion of the investigator is likely to impact the outcome measures in this study.
Exclusion Criteria:
- any infant that does not meet the inclusion criteria will not be included in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: LCPUFA Supplement
DHA/ARA supplement providing 200 mg/day docosahexaenoic acid (DHA) from DHASCO®-S oil and 200 mg/day arachidonic acid (ARA) from ARASCO® oil (DSM Nutritional Products).
|
Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
|
|
PLACEBO_COMPARATOR: A Placebo
400 mg/day corn oil
|
Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Developmental test scores
Time Frame: 12 months (at 24 months of age)
|
Bayley Scales of Infant and Toddler Development 3rd Edition and Beery-Buktenica Developmental Test of Visual -Motor Integration (5th Ed) composite scores at 24 months in relation to LCPUFA supplement group.
|
12 months (at 24 months of age)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma and Red Blood Cell fatty acids (% total fatty acids)
Time Frame: 12 months (at 24 months of age)
|
Plasma and red blood cell fatty acids levels in relation to dietary LCPUFA intake
|
12 months (at 24 months of age)
|
|
Systolic and diastolic blood pressure (mmHg)
Time Frame: 12 months (at baseline and 24 months of age)
|
In clinic systolic and diastolic blood pressure in relation to LCPUFA status
|
12 months (at baseline and 24 months of age)
|
|
Heart rate and heart rate variability
Time Frame: 12 months (at baseline and 24 months of age)
|
Heart rate and heart rate variability in relation to LCPUFA status
|
12 months (at baseline and 24 months of age)
|
|
Genetic variation in fatty acid desaturases
Time Frame: 12 months (at 24 months of age)
|
Genetic variation in fatty acid desaturases in relation to LCPUFA status
|
12 months (at 24 months of age)
|
|
Hemoglobin (g/dL)
Time Frame: 12 months (at baseline and 24 months of age)
|
Hemoglobin concentration in relation to diet
|
12 months (at baseline and 24 months of age)
|
|
Ferritin (ng/ml)
Time Frame: 12 months (at baseline and 24 months of age)
|
Serum ferritin in relation to child diet
|
12 months (at baseline and 24 months of age)
|
|
Choline metabolites (umol/L)
Time Frame: 12 months (at baseline and 24 months of age)
|
Plasma free choline, betaine, and dimethylglycine in relation to child diet
|
12 months (at baseline and 24 months of age)
|
|
Folate (nmol/L)
Time Frame: 12 months (at baseline and 24 months of age)
|
Serum folate in relation to child diet
|
12 months (at baseline and 24 months of age)
|
|
Vitamin B12 (pmol/L)
Time Frame: 12 months (at baseline and 24 months of age)
|
Serum vitamin B12 in relation to child diet
|
12 months (at baseline and 24 months of age)
|
|
Vitamin D (nmol/L)
Time Frame: 12 months (at baseline and 24 months of age)
|
Serum vitamin D in relation to child diet
|
12 months (at baseline and 24 months of age)
|
|
Supplements and supplemented foods
Time Frame: 12 months (at baseline and age 18 and 24 months)
|
Use of nutrient supplements and supplemented foods and child nutrient status.
|
12 months (at baseline and age 18 and 24 months)
|
|
Growth (weight, kg)
Time Frame: 12 months (at baseline and age 18 and 24 months)
|
Weight of at baseline, 18 and 24 months in relation to LCPUFA
|
12 months (at baseline and age 18 and 24 months)
|
|
Growth (height)
Time Frame: 12 months (at baseline and age 18 and 24 months)
|
Height at baseline, 18 and 24 months in relation to LCPUFA
|
12 months (at baseline and age 18 and 24 months)
|
|
Growth (BMI, kg/m2)
Time Frame: 12 months (at baseline and age 18 and 24 months)
|
BMI at baseline, 18 and 24 months in relation to LCPUFA
|
12 months (at baseline and age 18 and 24 months)
|
|
Growth (waist circumference, cm)
Time Frame: 12 months (at baseline and age 18 and 24 months)
|
Waist circumference at baseline, 18 and 24 months in relation to LCPUFA
|
12 months (at baseline and age 18 and 24 months)
|
|
Incidence and duration of illness
Time Frame: 12 months (at baseline and age 18 and 24 months)
|
Parental reports of illness and duration
|
12 months (at baseline and age 18 and 24 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Angela Devlin, PhD, The University of British Columbia
Publications and helpful links
General Publications
- Devlin AM, Chau CMY, Dyer R, Matheson J, McCarthy D, Yurko-Mauro K, Innis SM, Grunau RE. Developmental Outcomes at 24 Months of Age in Toddlers Supplemented with Arachidonic Acid and Docosahexaenoic Acid: Results of a Double Blind Randomized, Controlled Trial. Nutrients. 2017 Sep 6;9(9):975. doi: 10.3390/nu9090975.
- Wiedeman AM, Dyer RA, McCarthy D, Yurko-Mauro K, Innis SM, Devlin AM. Biomarkers of Docosahexaenoic Acid but Not Arachidonic Acid Reflect Dietary Intakes in Toddlers at Ages 1 and 2 Years Who Are Not Meeting Dietary Recommendations. J Nutr. 2020 Mar 1;150(3):518-525. doi: 10.1093/jn/nxz280.
- Wiedeman AM, Chau CMY, Grunau RE, McCarthy D, Yurko-Mauro K, Dyer RA, Innis SM, Devlin AM. Plasma Betaine Is Positively Associated with Developmental Outcomes in Healthy Toddlers at Age 2 Years Who Are Not Meeting the Recommended Adequate Intake for Dietary Choline. J Nutr. 2018 Aug 1;148(8):1309-1314. doi: 10.1093/jn/nxy108.
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- H09-02028
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.